Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sirolimus--challenging current perspectives.

Irina Buhaescu1, Hassan Izzedine, Adrian Covic

  • 1Dialysis and Renal Transplantation Center, Parhon University Hospital, Iasi, Romania. irinabuhaescu@yahoo.fr

Therapeutic Drug Monitoring
|October 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024
Same author

The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration.

Kidney international·2024
Same author

Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states.

Clinical kidney journal·2024
Same author

Exploring the nexus: The place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum.

European journal of internal medicine·2024
Same author

Metabolically healthy obesity and chronic kidney disease risk: exploring the dynamics.

Panminerva medica·2024
Same author

Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024
Same journal

Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography.

Therapeutic drug monitoring·2026
Same journal

Deltamethrin Placental Transfer and Seasonal Pyrethroid Exposure: A Mother-Newborn Dyad Pilot Study.

Therapeutic drug monitoring·2026
Same journal

A Clustering-Based Grey Modeling Approach for Tacrolimus Concentration Prediction Under Sparse Therapeutic Drug Monitoring.

Therapeutic drug monitoring·2026
Same journal

Response to Panteghini "About Analytical Performance Specifications for Immunosuppressive Drug Measurements".

Therapeutic drug monitoring·2026
Same journal

Lacosamide Concentration in Various Biological Matrices (Plasma, Saliva, and Hair) Does Not Correlate with Clinical Outcomes in Patients with Epilepsy.

Therapeutic drug monitoring·2026
Same journal

Comparison of Creatinine-Based, Cystatin C-Based, and Combined Kidney Function Estimates for Vancomycin Clearance Prediction.

Therapeutic drug monitoring·2026
See all related articles

Sirolimus, an mTOR inhibitor, is crucial for transplant immunosuppression. This review details its unexpected side effects, particularly pulmonary and renal toxicity, and explores new therapeutic uses.

Area of Science:

  • Immunology
  • Pharmacology
  • Nephrology

Background:

  • Sirolimus (rapamycin) is a potent immunosuppressant targeting the mammalian target of rapamycin (mTOR) pathway.
  • It effectively inhibits T- and B-lymphocyte proliferation, making it vital in organ transplantation.
  • While established side effects are known, novel and severe adverse events are increasingly recognized.

Purpose of the Study:

  • To review recent data on unexpected side effects of sirolimus, focusing on pulmonary and renal toxicity.
  • To discuss sirolimus's application in renal transplantation and its emerging therapeutic roles.
  • To provide an overview of sirolimus therapeutic drug monitoring, pharmacokinetics, and drug interactions.

Main Methods:

  • Literature review of recent data on sirolimus.

Related Experiment Videos

  • Focus on unexpected side effects, particularly pulmonary and renal toxicity.
  • Exploration of new therapeutic indications and drug monitoring aspects.

    • Main Results:

    • Sirolimus use is associated with classical side effects like hematological issues and hypercholesterolemia.
    • Emerging data highlight potentially severe pulmonary and renal toxicities.
    • New therapeutic applications in chronic glomerulopathies, polycystic kidney disease, and cancers are under investigation.

    Conclusions:

    • Sirolimus remains a key immunosuppressant, but careful monitoring for unexpected toxicities is essential.
    • Its potential benefits extend beyond transplantation, warranting further research into new indications.
    • Understanding sirolimus pharmacokinetics, interactions, and monitoring is crucial for optimizing patient outcomes.